BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 28017293)

  • 1. Decline in acute urinary toxicities with increased institutional experience: 15-year experience of permanent seed prostate brachytherapy in a single Australasian institution.
    Ong WL; Matheson B; Millar J
    Brachytherapy; 2017; 16(2):313-322. PubMed ID: 28017293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The utility of transition zone index in predicting acute urinary morbidity after 125I prostate brachytherapy.
    Crook J; Toi A; McLean M; Pond G
    Brachytherapy; 2002; 1(3):131-7. PubMed ID: 15090275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decline in acute urinary toxicity: a long-term study in 2011 patients with prostate brachytherapy within a provincial institution.
    Chan EK; Keyes M; Pickles T; Lapointe V; Spadinger I; McKenzie M; Morris WJ
    Brachytherapy; 2014; 13(1):46-52. PubMed ID: 24210697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severity categories of the International Prostate Symptom Score before, and urinary morbidity after, permanent prostate brachytherapy.
    Gutman S; Merrick GS; Butler WM; Wallner KE; Allen Z; Galbreath RW; Adamovich E
    BJU Int; 2006 Jan; 97(1):62-8. PubMed ID: 16336330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genitourinary toxicity after permanent iodine-125 seed implantation: The nationwide Japanese prostate cancer outcome study of permanent iodine-125 seed implantation (J-POPS).
    Tanaka N; Yorozu A; Kikuchi T; Higashide S; Kojima S; Ohashi T; Katayama N; Nakamura K; Saito S; Dokiya T; Fukushima M;
    Brachytherapy; 2019; 18(4):484-492. PubMed ID: 31072729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pretreatment nomogram to predict the risk of acute urinary retention after I-125 prostate brachytherapy.
    Roeloffzen EM; van Vulpen M; Battermann JJ; van Roermund JG; Saibishkumar EP; Monninkhof EM
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):737-44. PubMed ID: 20888131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of acute urinary retention after iodine-125 prostate brachytherapy on health-related quality of life.
    Roeloffzen EM; Hinnen KA; Battermann JJ; Monninkhof EM; van Roermund JG; van Gellekom MP; Frank SJ; van Vulpen M
    Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1322-8. PubMed ID: 19939578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary symptom flare following I-125 prostate brachytherapy.
    Cesaretti JA; Stone NN; Stock RG
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):1085-92. PubMed ID: 12829146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of experience and technical changes on acute urinary and rectal morbidity in low-dose prostate brachytherapy using loose seeds real-time implantation.
    Le Fur E; Malhaire JP; Nowak E; Rousseau B; Erauso A; Pene-Baverez D; Papin G; Delage F; Perrouin-Verbe MA; Fournier G; Pradier O; Valeri A
    Brachytherapy; 2013; 12(6):589-95. PubMed ID: 23669150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation.
    Crook J; McLean M; Catton C; Yeung I; Tsihlias J; Pintilie M
    Int J Radiat Oncol Biol Phys; 2002 Feb; 52(2):453-60. PubMed ID: 11872292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preimplant predictive factors of urinary retention after iodine 125 prostate brachytherapy.
    Mabjeesh NJ; Chen J; Stenger A; Matzkin H
    Urology; 2007 Sep; 70(3):548-53. PubMed ID: 17905113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decline in urinary retention incidence in 805 patients after prostate brachytherapy: the effect of learning curve?
    Keyes M; Schellenberg D; Moravan V; McKenzie M; Agranovich A; Pickles T; Wu J; Liu M; Bucci J; Morris WJ
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):825-34. PubMed ID: 16458775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modified transurethral resection of the prostate (TURP) for men with moderate lower urinary tract symptoms (LUTS) before brachytherapy is safe and feasible.
    Brousil P; Hussain M; Lynch M; Laing RW; Langley SE
    BJU Int; 2015 Apr; 115(4):580-6. PubMed ID: 24802744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose to the bladder neck in MRI-guided high-dose-rate prostate brachytherapy: Impact on acute urinary toxicity and health-related quality of life.
    Sanmamed N; Chung P; Berlin A; Adleman J; Borg J; Lao B; Ghai S; Weersink R; Simeonov A; Rink A; Menard C; Helou J
    Brachytherapy; 2019; 18(4):477-483. PubMed ID: 31109872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of continence following 532 nm laser prostatectomy for patients previously treated with radiation therapy or brachytherapy.
    No D; Osterberg EC; Otto B; Naftali I; Choi B
    Lasers Surg Med; 2013 Aug; 45(6):358-61. PubMed ID: 23813669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of dose on risk of acute urinary retention after iodine-125 prostate brachytherapy.
    Roeloffzen EM; Battermann JJ; van Deursen MJ; Monninkhof EM; Visscher MI; Moerland MA; van Vulpen M
    Int J Radiat Oncol Biol Phys; 2011 Jul; 80(4):1072-9. PubMed ID: 20615621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors predicting for urinary morbidity following 125iodine transperineal prostate brachytherapy.
    Williams SG; Millar JL; Duchesne GM; Dally MJ; Royce PL; Snow RM
    Radiother Oncol; 2004 Oct; 73(1):33-8. PubMed ID: 15465143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients.
    Keyes M; Miller S; Moravan V; Pickles T; McKenzie M; Pai H; Liu M; Kwan W; Agranovich A; Spadinger I; Lapointe V; Halperin R; Morris WJ
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1023-32. PubMed ID: 19111402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urethra-sparing, intraoperative, real-time planned, permanent-seed prostate brachytherapy: toxicity analysis.
    Zilli T; Taussky D; Donath D; Le HP; Larouche RX; Béliveau-Nadeau D; Hervieux Y; Delouya G
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e377-83. PubMed ID: 21514068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peak flow rate is the best predictor of acute urinary retention following prostate brachytherapy: our experience and literature review.
    Ikeda T; Shinohara K
    Int J Urol; 2009 Jun; 16(6):558-60. PubMed ID: 19456987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.